| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
John Canan is Director at REVG and has filed Form 4s across 2 companies. John Canan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.7M at current prices.
The biggest single holding is TEX (~$3.7M) as Director.
John Canan has 14 Form 4 filings on record from January 2017 to February 2026, across 3 companies: Director at Terex (TEX), 2026; Director at REV Group (REVG), 2017–2025; Director at Grace Therapeutics (GRCE), 2021–2022.
The 17 reported transactions were 12 stock awards, 3 open-market purchases and 2 option or other derivative awards.
Counted by filing, the open-market trades come to 1 purchase worth about $81K and no sales.
The only open-market purchase was 5,040 shares of REVG at an average $16.04 on June 25, 2018, about $81K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 25, 2018 | REVG Rev Group, Inc. | Director | Buy | 5,040 | $16.04 | $80,845.16 | +381.0% |